View Item 

Show simple item record

Improved Transplant‐Free Survival in Patients With Systemic Sclerosis–Associated Pulmonary Hypertension and Interstitial Lung Disease
dc.contributor.authorVolkmann, Elizabeth R.en_US
dc.contributor.authorSaggar, Rajeeven_US
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorTorres, Bryanten_US
dc.contributor.authorFlora, Arjanen_US
dc.contributor.authorYoder, Lynneen_US
dc.contributor.authorClements, Philip J.en_US
dc.contributor.authorElashoff, Robert M.en_US
dc.contributor.authorRoss, David J.en_US
dc.contributor.authorAgrawal, Harshen_US
dc.contributor.authorBorazan, Nabeelen_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorSaggar, Rajanen_US
dc.date.accessioned2014-07-03T14:41:16Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-07-03T14:41:16Z
dc.date.issued2014-07en_US
dc.identifier.citationVolkmann, Elizabeth R.; Saggar, Rajeev; Khanna, Dinesh; Torres, Bryant; Flora, Arjan; Yoder, Lynne; Clements, Philip J.; Elashoff, Robert M.; Ross, David J.; Agrawal, Harsh; Borazan, Nabeel; Furst, Daniel E.; Saggar, Rajan (2014). "Improved Transplant‐Free Survival in Patients With Systemic Sclerosis–Associated Pulmonary Hypertension and Interstitial Lung Disease." Arthritis & Rheumatology 66(7): 1900-1908.en_US
dc.identifier.issn2326-5191en_US
dc.identifier.issn2326-5205en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107488
dc.publisherWiley Periodicals, Inc.en_US
dc.titleImproved Transplant‐Free Survival in Patients With Systemic Sclerosis–Associated Pulmonary Hypertension and Interstitial Lung Diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelRheumatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107488/1/art38623.pdf
dc.identifier.doi10.1002/art.38623en_US
dc.identifier.sourceArthritis & Rheumatologyen_US
dc.identifier.citedreferenceLaunay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al. Clinical characteristics and survival in systemic sclerosis‐related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140: 1016 – 24.en_US
dc.identifier.citedreferenceO'Callaghan DS, Humbert M. A critical analysis of survival in pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 218 – 22.en_US
dc.identifier.citedreferenceCondliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease‐associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151 – 7.en_US
dc.identifier.citedreferenceMathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569 – 77.en_US
dc.identifier.citedreferenceLe Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63: 2456 – 64.en_US
dc.identifier.citedreferenceChung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease‐associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383 – 94.en_US
dc.identifier.citedreferenceSadushi‐Kolici R, Skoro‐Sajer N, Zimmer D, Bonderman D, Schemper M, Klepetko W, et al. Long‐term treatment, tolerability, and survival with sub‐cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 2012; 31: 735 – 43.en_US
dc.identifier.citedreferenceLeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573 – 6.en_US
dc.identifier.citedreferenceSimonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43 – 54.en_US
dc.identifier.citedreferenceGoh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248 – 54.en_US
dc.identifier.citedreferenceBadesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, et al. Longterm survival among patients with scleroderma‐associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009; 36: 2244 – 9.en_US
dc.identifier.citedreferenceLefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis–associated pulmonary hypertension: a systematic review and meta‐analysis. Arthritis Rheum 2013; 65: 2412 – 23.en_US
dc.identifier.citedreferenceFarber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32: 1114 – 22.en_US
dc.identifier.citedreferenceMcLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573 – 619.en_US
dc.identifier.citedreferenceDelcroix M, Spaas K, Quarck R. Long‐term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. Eur Respir Rev 2009; 18: 253 – 9.en_US
dc.identifier.citedreferenceGhofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895 – 900.en_US
dc.identifier.citedreferenceBenza RL, Gomberg‐Maitland M, Naeije R, Arneson CP, Lang IM. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo‐controlled trials. J Heart Lung Transplant 2011; 30: 982 – 9.en_US
dc.identifier.citedreferenceBadesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425 – 34.en_US
dc.identifier.citedreferenceMontani D, Jais X, Price LC, Achouh L, Degano B, Mercier O, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno‐occlusive disease. Eur Respir J 2009; 34: 1348 – 56.en_US
dc.identifier.citedreferenceDorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893 – 902.en_US
dc.identifier.citedreferenceColombat M, Mal H, Groussard O, Capron F, Thabut G, Jebrak G, et al. Pulmonary vascular lesions in end‐stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38: 60 – 5.en_US
dc.identifier.citedreferenceBadagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant 2012; 31: 364 – 72.en_US
dc.identifier.citedreferenceFransen J, Popa‐Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5‐year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788 – 92.en_US
dc.identifier.citedreferenceLaunay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis‐associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940 – 6.en_US
dc.identifier.citedreferenceSteen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283 – 9.en_US
dc.identifier.citedreferenceMoore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high‐resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis‐related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155 – 60.en_US
dc.identifier.citedreferenceHumbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long‐term survival. Arthritis Rheum 2011; 63: 3522 – 30.en_US
dc.identifier.citedreferenceHassoun PM, Shafiq M. Tackling the challenges of systemic sclerosis–associated pulmonary hypertension: one step forward [editorial]. Arthritis Rheum 2013; 65: 2240 – 2.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art38623.pdf
Size:
234.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.